| abstract |
The invention relates to quinazolines of general formula (I), in which Ra, R b and n are defined as referred to in Claim No. 1, to their tautomers, their stereoisomers, and to their salts, particularly their physiologically compatible salts with inorganic or organic acids or bases, which have valuab le pharmacological properties, in particular, an inhibitive effect on the signa l transduction imparted by tyrosine kinases. The invention also relates to the use of said quinazolines for treating diseases, especially tumor diseases, disorders of the lung and of the respiratory tract, and to the production thereof. |